RxDoctor Payments Data

Phuong Nguyen, MD

Infectious Disease · Zephyrhills, FLNPI 1811159262

Payments from drug & device makers

$849in general payments, 2019–2025

Across 38 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$134
  • Insmed, Inc.$115
  • ETS Wound Care LLC$103
  • Sanofi$49
  • KCI USA, Inc.$48
  • Convatec Inc.$36
  • plus $363 from 19 others

What the payments were for

  • Food & beverage$73386%
  • Education$11514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$849 in reported general payments places this provider in the 50th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$292,364
Medicare patients
560
Services billed
3,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala73$322,820
JulucaDolutegravir/Rilpivirine27$90,995
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf18$86,603
DescovyEmtricitabine/Tenofov Alafenam34$71,443
OdefseyEmtricitab/Rilpiviri/Tenof Ala18$60,639
TivicayDolutegravir Sodium24$53,095
ErtapenemErtapenem Sodium120$50,490
Daptomycin94$34,216
Cefepime Hcl171$32,550
Meropenem136$22,211
Vancomycin Hcl89$13,563
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam47$10,397
CeftriaxoneCeftriaxone Sodium69$10,236
Cefpodoxime Proxetil29$7,334
Fluconazole241$6,860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$31$394,263107 claims
Viiv Healthcare CompanyJuluca, Tivicay$20$144,09051 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Zephyrhills

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →